Skip to main content
. 2022 Oct 5;48(11):1191–1197. doi: 10.1097/DSS.0000000000003585

Figure 1.

Figure 1.

Phase 3 study designs and injection sites: Studies 098,11 099,12 142,13 and 143.14 CFL, crow's feet lines; FHL, forehead lines; GL, glabellar lines.